Renal Cell Carcinoma
Local therapy for mRCC
Образовательная цель: Identify patients with metastatic ccRCC who will benefit the most from immediate, deferred or no cytoreductive nephrectomy (CN) and metastasis-directed therapy.
Специальность: Urology, Medical oncology, Clinical oncology
Целевая аудитория : Specialists (CME: basic, intermediate), Residents (senior)
Самое последнее обновление : May 2024
Фон:
The role of CN and metastasis-directed therapy (including surgery, ablative therapies and radiotherapy) in the treatment of mRCC is evolving. However, the precise role of CN and its timing in relation to systemic therapy remains controversial.